Adiposity markers and risk of coronary heart disease in patients with type 2 diabetes mellitus by Simone F Tonding et al.
Tonding et al. Nutrition Journal 2014, 13:124
http://www.nutritionj.com/content/13/1/124RESEARCH Open AccessAdiposity markers and risk of coronary heart
disease in patients with type 2 diabetes mellitus
Simone F Tonding1,2, Flávia M Silva1,2, Juliana P Antonio1,2, Mirela J Azevedo1,2,3, Luis Henrique S Canani1,2,3
and Jussara C Almeida1,2,3*Abstract
Background: This cross-sectional study aimed to evaluating the association between body adiposity markers and
high-risk of coronary heart disease (CHD) in patients with type 2 diabetes.
Methods: Recent adiposity markers [waist-to-height ratio, conicity index (C-index) and body adiposity index] and
traditional markers [BMI, waist circumference and waist-to-hip ratio (WHR)] were measured. The 10-year risk of fatal
CHD was estimated according to UKPDS risk engine scores. Patients were divided into high (CHD risk ≥20%; n = 99)
or low-moderate (CHD risk <20%; n = 321) risk groups. Multiple logistic regression models were performed to
analyze associations between CHD risk (outcome) and adiposity markers.
Results: A total of 420 patients with type 2 diabetes (61.9 ± 9.5 years; 53.5% females; HbA1c 7.6 ± 1.6%) were
evaluated. The high risk group had greater proportions of elevated C-index and BMI values than patients with
low-moderate risk. No between-group differences in other adiposity markers were observed. In multiple logistic
regression models, only C-index values ≥1.35 were associated with CHD risk >20% (OR = 1.69; 95% CI 1.03-2.78;
P = 0.039) after adjusting for confounders (sedentary lifestyle, diabetic nephropathy, serum creatinine, and diabetes
duration). The association between WHR and CHD risk did not hold in this sample.
Conclusions: The C-index was the body adiposity marker best associated with high risk of fatal CHD in these
patients with type 2 diabetes.
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Cardiovascular disease is the leading cause of morbidity
and mortality in patients with type 2 diabetes [1,2]. In
these patients, the risk of death from vascular causes is
2.32 times higher than in persons without diabetes [3],
and diabetes was once considered a coronary heart disease
(CHD) risk equivalent [2]. This concept was reinforced by
a seminal population-based cohort study conducted in
Finland in the late 1990s [4], which study suggested that
the risk of coronary events of diabetic patients without
previous myocardial infarction was similar to that of non-
diabetic patients with a history of myocardial infarction.
However, this observation was not confirmed in other* Correspondence: jcalmeida@hcpa.ufrgs.br
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unless otherwise stated.population samples [5]. Indeed, it is now recognized that
CVD risk varies among patients with diabetes, and that
accurate estimation of risk clearly depends on individual
characteristics [6]. Hence, the identification of patients
with elevated cardiovascular disease risk plays an import-
ant role in the development of strategies to prevent car-
diovascular events and to reinforce existing interventions.
The American Diabetes Association has recommended in-
dividualized risk assessment for primary prevention using
designed risk prediction models and algorithms [6].
As obesity is present in 80% of patients with type 2 dia-
betes [1] and is considered an independent risk factor for
cardiovascular disease, its evaluation and treatment in
these patients is extremely important [7]. Anthropometric
markers are useful tools for assessment of overweight and/
or obesity in clinical practice, and it has been suggested
that these markers may be good predictors of cardiovascu-
lar risk [8]. BMI is the main predictor used to quantifyl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(WC), waist-hip ratio (WHR), waist-height ratio (WHtR),
and the conicity index (C-index) are markers of central
body fat accumulation, and the body adiposity index
(BAI) is a predictor of whole body adiposity [9].
The WHR and WHtR are good predictors of cardiovas-
cular risk in patients with type 2 diabetes [10,11] and are
considered traditional anthropometric markers, as are the
BMI and WC. The role of these measurements in CHD risk
assessment has been recently debated [12], and WHtR
seems to be a more accurate risk marker than BMI and
WC [13,14] in the general population and in a sample of
Chinese patients with diabetes [11]. Some novel body adi-
posity markers (C-index and BAI) have also been proposed,
but evidence on their association with cardiovascular risk
in patients with diabetes is scarce. This study sought to
evaluate the potential association between body adiposity
markers and high-risk of CHD as determined by the United
Kingdom Prospective Diabetes Study (UKPDS) score in
outpatients with type 2 diabetes.
Methods
Study population
This cross-sectional study was conducted in patients with
type 2 diabetes from the Group of Nutrition in Endocrin-
ology cohort. The study sample comprised 420 patients
with type 2 diabetes (53.5% women, mean age 61.9 ±
9.5 years). All patients underwent clinical, anthropometric,
and laboratory assessment. The diagnosis of diabetes was
established if the fasting plasma glucose was ≥ 126 mg/dl
or the 2-h plasma glucose value after a 75-g oral glucose
tolerance test was ≥200 mg/dl. In the absence of unequivo-
cal hyperglycemia, these results were always confirmed.
Type 2 diabetes was defined as onset of hyperglycemia
after the age of 30 years, with no history of ketoacidosis
or documented ketonuria, and no insulin treatment in
the first 5 years after diagnosis of diabetes [1]. Patients
seen consecutively by the nutrition team at the Endocrin-
ology Division of Hospital de Clinicas de Porto Alegre,
Brazil, recruited from 2001 to 2010, were selected on the
basis of the following criteria: age <80 years; serum creatin-
ine <2.0 mg/dl; normal liver and thyroid function tests; ab-
sence of urinary tract infection or other renal disease; and
absence of severe autonomic neuropathy (presence of
symptomatic postural hypotension, gastroparesis or dia-
betic diarrhea). The study was conducted in accordance
with Declaration of Helsinki guidelines, and all procedures
involving patients were approved by the Hospital de Clini-
cas de Porto Alegre Research Ethics Committee. Written
informed consent was obtained from all patients.
Clinical and anthropometric evaluation
Sitting blood pressure was measured twice, after a 10-
minute rest, using a digital sphygmomanometer (OmronHEM-705CP Kunotsubo, Terado-cho, Muko, Kyoto,
617–0002, Japan). Hypertension was defined as blood
pressure ≥140/90 mmHg on two separate occasions or
use of antihypertensive drugs [2]. According to a random
spot urine sample or 24-h timed urine collection, patients
were defined as normoalbuminuric (urinary albumin ex-
cretion [UAE] <17 mg/l or <20 mcg/min), microalbumi-
nuric (UAE 17–174 mg/l or 20–199 mcg/min), or
macroalbuminuric (UAE >175 mg/l or >199 mcg/min).
The diagnosis of micro- and macroalbuminuria was al-
ways confirmed in two out of three urine samples [15]. A
dilated fundus examination was performed and diabetic
retinopathy was graded when present [16]. Physical activ-
ity was graded in levels according to activities during a
typical day, based on a standardized questionnaire [17]
adapted to local habits (namely, skiing was removed from
the physical activity options). Four levels were defined,
ranging from physically inactive to high physical activity.
Patients were considered physically inactive when their ac-
tivities during a typical day were best represented by the
sentence “I read, watch television and do housework with
little physical effort”. Alcohol intake was considered posi-
tive in patients who mentioned current intake of any alco-
holic beverage in a short standardized questionnaire.
Patients were classified as current smokers or non-
smokers. Ethnicity was self-reported as white (Latino) or
non-white.
Body weight and height (measured with patients bare-
foot and wearing light clothing) were obtained using an
anthropometric scale (Filizola, Filizola Balanças Indus-
triais S.A., São Paulo, Brazil), with measurements re-
corded to the nearest 50 g for weight and to the nearest
0.1 cm for height. WC was measured at the midpoint
between the lowest rib and the iliac crest, and hip cir-
cumference, at the most prominent point of the gluteus
maximus [18]. Both measurements were obtained using
flexible, non-stretch fiberglass tape. Based on anthropo-
metric and laboratory data, the body adiposity markers
of interest were estimated using the formulas described
below:
1. Body Mass Index (BMI) [19]: body weight (kg)/
height (meters) squared
2. Waist-to-hip ratio (WHR) [19]: waist circumference
(cm)/ hip circumference (cm)
3. Waist-to-height ratio (WHtR) [20]: waist
circumference (cm)/ height (cm)
4. Conicity index (C-index) [21]: waist circumference cmð Þ
0:109
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
body weight kgð Þ
height mð Þ
q





No specific model for prediction of cardiovascular risk
in Latin American populations exists. Therefore, the risk
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gine score [22]. This score has been validated specifically
for patients with diabetes [23] and provides an estimate
of risk for a new CHD event and stroke (fatal and nonfa-
tal) at 5 and 10 years [22].
The data used to calculate the UKPDS risk score (available
at http://www.dtu.ox.ac.uk/riskengine/download.php) were:
glycosylated hemoglobin (HbA1c), systolic blood pressure,
serum total cholesterol and high-density lipoprotein
(HDL) cholesterol, atrial fibrillation, gender, age, ethnicity,
smoking, and diabetes duration. Fatal CHD risk was esti-
mated for 10 years [22]. Subjects with risk scores higher
than 20% were classified as high-risk, whereas those with
a risk score lower than 20% were classified into the low-
moderate risk group.
Laboratory measurements
Blood samples were obtained after a 12-h fast. Plasma glu-
cose was determined by a glucose oxidase method [24],
hemoglobin A1c (reference range, 4.7 to 6.0%) by HPLC
(Tosoh 2.2 Plus HbA1c; Tosoh Corporation, Tokyo, Japan)
[25], total cholesterol [26] and triglycerides [27] by enzym-
atic colorimetric methods (Merck Diagnostica, Darmstadt,
Germany; Boehringer Mannheim, Buenos Aires, Argentina),
and high-density lipoprotein cholesterol (HDL) by the
homogeneous direct method (enzymatic colorimetric reac-
tion, ad described by Fletcher and modified by Farish) [28].
Low-density lipoprotein cholesterol (LDL) was calculated
using Friedewald’s formula [29] only for patients with
values <40 0 mg/dl. UAE was measured by immunoturbi-
dimetry (MicroAlb Sera-Pak® Immunomicroalbuminuria;
Bayer, Tarrytown, NY, USA) on a Cobas Mira Plus®
analyzer (Roche, Indianapolis, IN, USA) [30]. Creatinine
values were quantitated by Jaffe’s reaction [31].
Statistical analyses
Considering that this study aimed to evaluate the associ-
ation between body adiposity markers and high risk
of CHD, patients were divided into high-risk (CHD
risk ≥20%; n = 99) or low-moderate risk (CHD risk <20%;
n = 321) groups, and their demographic, clinical, and la-
boratory parameters were compared by Student’s t-test,
the Mann–Whitney U test, and the chi-square test as
appropriate. All analyses were carried out in the PASW
Statistics 18.0 software suite (SPSS Inc., Chicago, IL).
Data are described as mean ± SD, median (interquartile
range), or n (%). The type I error rate was set at P < 0.05
(two-tailed).
The adiposity markers were converted to categorical
variables (normal vs. abnormal values) in accordance
with established cutoff values available in the literature
(BMI ≥30 kg/m2 [19], WC >80 cm for females or >94 cm
for males [32], WHR >0.85 for females or >0.90 for
males [16], and WHtR >0.5 [33]). Regarding the BAI andC-index, mean values – for the C-index, > 1.35; for the
BAI, >35 for females or >25 for males – were adopted due
to absence of established cutoff values. The receiver oper-
ating characteristic (ROC) curve performance of these adi-
posity markers to identify 10-year CHD risk in type
2 diabetes has been demonstrated elsewhere, and the
C-index and BAI cutoff values were identified by sensitiv-
ity and specificity equilibrium [34]. The association be-
tween adiposity markers (dichotomous variable) and
presence of high CHD risk (dependent variable) was eval-
uated by multiple logistic regression analyses, adjusted for
potential confounders selected according to clinical rele-
vance or significance on univariate analyses.
Results
The study sample comprised 420 patients with type 2
diabetes, of whom 23.6% were classified as being at high
risk (UKPDS risk score >20%) for fatal CHD events;
mean UKPDS score was 37.0 ± 11.4% (95% CI 34.7 –
39.3%). The demographic, clinical, lifestyle, and labora-
tory characteristics of patients according to CHD risk
are shown in Table 1. Patients in the high-risk group
had a higher proportion of micro- and macroalbumi-
nuria, were more physically inactive, and had higher
fasting plasma glucose, LDL-cholesterol, triglycerides,
and serum creatinine levels than did patients in the low-
moderate risk group (all P values < 0.05). The parameters
that represent the components of the UKPDS risk score
were, as expected, significantly different between the two
groups, except for HDL-cholesterol values in women
(P = 0.246). Evaluation of diabetic retinopathy was avail-
able for 307 subjects. In this subgroup, patients with a
high CHD risk had a higher proportion of diabetic retin-
opathy (53.3%) than patients with low-moderate risk
(38.4%; P = 0.031).
We conducted analyses considering adiposity marker
values as categorical variables. The proportion of pa-
tients with type 2 diabetes by CHD risk group with ab-
normal values of each adiposity marker is shown in
Table 2. The majority of patients had abnormally high
WC (86.0%), WHR (94.8%), or WHtR (96.9%), though
we did not observe any difference between the high
and low-moderate CHD risk groups. Conversely, greater
proportions of patients (both male and female) in the
high-risk group had elevated C-index and BMI values
than in the low-risk group. Half of all patients had ele-
vated BAI values (49.5%), with no significant between-
group difference.
Multiple logistic regression models were constructed
and used to evaluate possible associations between adi-
posity markers and high 10-year CHD risk scores
(Table 3). Only the C-index was associated with high
CHD risk: C-index values ≥1.35 increased the odds of
high CHD risk significantly (OR 1.69; 95% CI 1.03 – 2.78;
Table 1 Demographic, clinical, and laboratory profile of patients with type 2 diabetes, stratified by CHD risk
All patients High risk (≥20%) Low-moderate risk (<20%) P-value
N 420 99 321 -
Female 226 (53.5%) 31 (31.3%) 195 (60.7%) -
Age (years) 61.9 ± 9.5 68.1 ± 6.4 58.7 ± 9.2 -
Diabetes duration (years) 10.0 (6.0-17.0) 15.0 (9.0-22.0) 10.0 (5.0-15.0) -
White (Latino) ethnicity 348 (82.9%) 94 (94.9%) 254 (79.1%) -
Education (years) 7.2 ± 3.6 7.0 ± 3.5 7.3 ± 3.6 0.554a
Smoking
Current smokers 48 (11.4%) 13 (13.1%) 35 (10.9%)
Former smokers 175 (41.7%) 52 (52.5%) 123 (38.3%) -
Nonsmokers 197 (46.9%) 34 (34.3%) 163 (50.8%)
Current alcohol intake 132 (31.4%) 33 (33.3%) 99 (30.8%) 0.186b
Sedentary lifestyle 246 (58.7%) 63 (63.6%) 183 (57.2%) <0.001b
Micro- and macroalbuminuria 129 (31.0%) 41 (41.8%) 87 (27.4%) 0.007b
Current use of hypolipidemic drugs 151 (36.0%) 36 (36.4%) 115 (35.8%) 0.922b
Diabetes treatment
Diet 24 (5.7%) 3 (3.0%) 21 (6.5%)
Oral antidiabetics 245 (58.3%) 50 (50.5%) 195 (60.8%) 0.082b
Oral antidiabetics and/or insulin 151 (36.0%) 46 (46.5%) 105 (32.7%)
Hypertension 360 (85.7%) 85 (85.9%) 257 (81.0%) 0.195b
Systolic blood pressure (mmHg) 139 ± 21 143 ± 24 137 ± 20 -
Diastolic blood pressure (mmHg) 80 ± 12 79 ± 14 80 ± 12 0.407a
BMI (kg/m2) 28.8 ± 4.3 28.2 ± 4.5 28.9 ± 4.3 0.163a
Fasting plasma glucose (mg/dl) 149.8 ± 55.6 166.3 ± 64.8 144.7 ± 51.4 0.003a
Glycosylated hemoglobin (%) 7.6 ± 1.6 8.3 ± 2.0 7.3 ± 1.4 -
Total cholesterol (mg/dl) 201.2 ± 41.6 212.5 ± 42.5 197.7 ± 40.7 -
HDL cholesterol (mg/dl)
Female (n = 226) 51.9 ± 12.8 49.4 ± 11.5 52.3 ± 13.0 -
Male (n = 194) 46.2 ± 11.3 43.5 ± 10.0 47.7 ± 11.8 -
LDL cholesterol (mg/dl) 121.0 ± 35.5 130.6 ± 39.3 116.9 ± 34.4 0.002a
Triglycerides (mg/dl) 135.5 (100.0-201.0) 159.0 (117.0-236.0) 132.0 (94.5-186.0) <0.001c
Serum creatinine (mg/dl) 0.87 ± 0.23 0.94 ± 0.26 0.84 ± 0.22 <0.001a
Data expressed as means ± SD, median (interquartile range), or n (%). CHD, Coronary heart disease. Current alcohol intake available for 308 patients.
aStudent t test, bChi-square test, cMann–Whitney U test.
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style, diabetic nephropathy, serum creatinine, and diabetes
duration). When retinopathy was included as a confound-
ing variable in a sub-sample of patients (n = 307), the
C-index association with the presence of high CHD risk
followed a similar pattern (OR 1.91; 95% CI 1.08 – 3.35;
P = 0.025).
Discussion
In this study, a novel marker of adiposity, the C-index,
was associated with the 10-year risk of fatal CHD events
in patients with type 2 diabetes. C-index values above
1.35 increased the odds of high CHD risk by 69%, afteradjusting for sedentary lifestyle, diabetic nephropathy,
serum creatinine, and diabetes duration (years).
A positive association between the C-index and cardio-
vascular risk factors has already been demonstrated by other
authors [35,36], although none of these studies were con-
ducted in patients with diabetes, precluding comparison
with our results. Patients with type 2 diabetes exhibit in-
creased visceral and intermuscular adiposity - which is re-
lated to the presence of insulin resistance - as compared
with the general population [37] and this aspect may be ex-
plain partially the “Obesity Paradox” observed in our results.
Although it does not distinguish between visceral and sub-
cutaneous abdominal fat, the C-index is a comprehensive
Table 2 Adiposity marker classification in patients with type 2 diabetes, stratified by CHD risk
All patients High risk (≥20%) Low-moderate risk (<20%) Pa
n 420 99 321 -
Body mass index classification (WHO criteria)b 162 (38.6%) 30 (30.3%) 132 (41.1%) 0.030
Obesity (≥30.0 kg/m2)
Waist circumference (IDF criteria)c: 361 (86.0%) 83 (83.8%) 278 (86.6%) 0.294
>80 cm for females and >94 cm for males
Waist-to-hip ratio (WHO criteria)b: 398 (94.8%) 97 (98.0%) 301 (93.8%) 0.080
>0.85 for females and >0.90 for males
Waist-to-height ratiod: >0.5 407 (96.9%) 96 (97.0%) 311 (96.9%) 0.630
Conicity index (mean): >1.35 211 (50.2%) 60 (60.6%) 151 (47.0%) 0.012
Body adiposity index (mean): 208 (49.5%) 47 (47.5%) 161 (50.2%) 0.363
>35 for females and >25 for males
CHD, coronary heart disease. The 10-year risk of fatal CHD was estimated according to UKPDS risk engine scores. Data are expressed as number of patients with the
analyzed characteristic (%). aChi-square; abnormal levels for each adiposity marker defined as values higher than the sample mean (conicity and body adiposity indexes)
or using well-known cutoffs established in the literature: bWHO criteria (1998); cInternational Diabetes Federation criteria for the European population (2005); dBrowning
et al. (2010), Nutr Res Rev.
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for weight and height, which allows direct comparisons of
fat distribution between individuals and populations [21].
Traditionally, WC has been considered a risk factor
for all-cause mortality in adults, including cardiovascular
disease [38], though this was questioned in a recent
meta-analysis of 58 cohorts [12]. In the current study,
WC alone did not show any significant association with
cardiovascular risk. Possibly, WC measurement may be
relevant when combined with others variables, especially
height and weight, in the first step for identification of
CHD risk (hard outcomes) in clinical practice (screen-
ing), but this hypothesis should be tested. In a systematic
review and meta-analysis performed by Ashwell et al.
[13], the WHtR is described as a better screening tool
than WC to discriminate diabetes, hypertension, dyslip-
idemia, the metabolic syndrome, and cardiovascular out-
comes in adults. However, in our sample, no association
was observed between waist-to-height ratio and 10-year
risk of fatal CHD events.
Possible limitations of our study concern adoption of
the cardiovascular risk score as a surrogate endpointTable 3 Multiple logistic regression models: high 10-year CHD
Abnormal levels
Body mass index 1.59 (0.98-2.58)
Waist circumference 1.23 (0.66-2.30)
Waist-to-hip ratio 0.32 (0.07-1.42)
Waist-to-height ratio 0.96 (0.26-3.57)
Conicity index 1.72 (1.09-2.73)*
Body adiposity index 1,12 (0.71-1.76)
Analyses performed on 420 type 2 diabetic patients. Markers defined as abnormal w
or >94 cm for males; waist-to-hip ratio >0.85 for females or >0.90 for males; waist-t
or >25 for males. Adjusted model: sedentary lifestyle, nephropathy, serum creatinin
reference for regression models. *P <0.05.instead of CHD events or mortality and the absence of a
validated cardiovascular score for Brazilians or Latin
Americans with diabetes. Furthermore, the utility of the
UKPDS score in patients with diabetes duration of more
than 10 years is unclear, as the UKPDS cohort included
only newly diagnosed patients [22]. However, the impact
of diabetes duration on the performance of the UKPDS
risk engine was recently evaluated, and a similar dis-
crimination of the model for patients with diabetes dur-
ation >10 years or <10 years was demonstrated [23].
Accordingly, when analysis of our study sample was re-
stricted to patients with a diabetes duration of >10 years
(48.8% of patients), we observed the same pattern of as-
sociation between the C-index and high CHD risk (data
not shown). Another potential limitation is the cross-
sectional design of our study, which precludes evaluation
of the studied adiposity markers as actual risk factors for
CHD. Moreover, the C-index cutoff value needs to be
determined considering hard CHD endpoints. Still, our
exclusion criteria may have influenced in the proportion
of patients with higher cardiovascular risk and/or dia-
betic complications, in this way, the association betweenrisk (≥20% by UKPDS score) as dependent variable







hen: Body Mass Index ≥30 kg/m2; waist circumference >80 cm for females
o-height ratio >0.5; conicity index >1.35; body adiposity index >35 for females
e, and diabetes duration (years) as confounders. Normal levels were used as
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other populations of patients with type 2 diabetes.
The novelty of the present study lies in its demonstra-
tion that the C-index can make an important contribu-
tion to the interpretation of anthropometric parameters
commonly used in clinical practice, such as weight,
height, and WC. Furthermore, it can be readily used as a
non-laboratory tool for CHD risk screening in patients
with diabetes.
Conclusion
The C-index was associated with 10-year risk of fatal
CHD events in patients with type 2 diabetes. Neverthe-
less, the potential role of the C-index as a predictor of
high CHD risk in patients with diabetes should be con-
firmed in prospective studies using hard endpoints.
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